Shareholders of Blueprint Medicines Corporation (NASDAQ:BPMC) will be pleased this week, given that the stock price is up 19% to US$105 following its latest quarterly results. Revenues of US$149m reported a marginal miss, falling short of forecasts by 4.8%, but earnings were better than expected - statutory profits came in at US$0.01 per share, a nice change from the loss the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We've discovered 1 warning sign about Blueprint Medicines. View them for free.NasdaqGS:BPMC Earnings and Revenue Growth May 4th 2025

After the latest results, the 20 analysts covering Blueprint Medicines are now predicting revenues of US$720.4m in 2025. If met, this would reflect a sizeable 28% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 63% to US$0.88. Before this earnings announcement, the analysts had been modelling revenues of US$723.5m and losses of US$1.17 per share in 2025. Although the revenue estimates have not really changed Blueprint Medicines'future looks a little different to the past, with a very favorable reduction to the loss per share forecasts in particular.

View our latest analysis for Blueprint Medicines

There's been no major changes to the consensus price target of US$126, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Blueprint Medicines analyst has a price target of US$167 per share, while the most pessimistic values it at US$83.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Blueprint Medicines' past performance and to peers in the same industry. One thing stands out from these estimates, which is that Blueprint Medicines is forecast to grow faster in the future than it has in the past, with revenues expected to display 39% annualised growth until the end of 2025. If achieved, this would be a much better result than the 3.9% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 18% per year. Not only are Blueprint Medicines' revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

Story Continues

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Blueprint Medicines going out to 2027, and you can see them free on our platform here..

Plus, you should also learn about the  1 warning sign  we've spotted with Blueprint Medicines .

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments